INTRODUCTION
The inflammatory bowel diseases (IBDs) are a group of chronic inflammatory conditions affecting the gastrointestinal tract. IBD is marked by periods of active disease flare-ups followed by remissions, either of which can last variable periods of time. Although Crohn's disease and ulcerative colitis are the two major forms of IBD, there are a number of other less common forms of IBD, including indeterminate colitis and microscopic colitis. Whereas Crohn's disease can affect any portion of the gastrointestinal tract and is commonly patchy with a transmural inflammatory pattern, ulcerative colitis is limited to the large intestine and has a continuous inflammatory pattern that involves only the mucosa. A commonality between Crohn's disease and ulcerative colitis is a dysregulated immune response in the intestine. Based on current evidence, IBD develops in genetically susceptible individuals because of complex interactions between environmental stimuli, the genome, the microbiome, and an inappropriate mucosal immune response. Genome wide association studies (GWAS) and linkage analyses have established a strong genetic component to IBD (stronger in Crohn's disease than ulcerative colitis) with the identification of about 200 loci associated with the development of IBD [1] [2] [3] [4] [5] [6] [7] [8] 9 & , [10] [11] [12] [13] [14] [15] . However, this only accounts for 16-23% of the heritability of IBD [16] [17] [18] . Lack of concordance between twin siblings (one sibling is affected with IBD while the other is disease-free) has further established that other factors -epigenetics, epistasis, and environmental factors -influence the development of IBD [19] [20] [21] [22] . This review will discuss some of the current findings regarding the role of microRNAs (miRNAs) in the pathophysiology
OVERVIEW OF MICRORNAS
MicroRNAs are noncoding single stranded RNAs of 21-23 nucleotides derived from primary miRNA transcripts (pri-miRNA) of intergenic or intronic origin [23] . Originally discovered in the early 1990s, the first miRNA, Lin-4, regulates Caenorhabditis elegans development through repression of Lin-14 and Lin-28 [24, 25] . Despite this observation, the significance of miRNAs continued to be largely underappreciated until the early 2000s when they were recognized as a distinct class of RNAs. Prior to 2002, when miRNAs were named the breakthrough of the year, there were less than 500 miRNA publications. In 2015, as evidence of the import of miRNAs in health and disease, there were over 9000 miRNA publications in PubMed.
The primary function of miRNAs is to regulate gene expression at the posttranscriptional level. This begins with the biogenesis of miRNAs. miRNAs are transcribed as longer pri-miRNAs of several hundred nucleotides from either a distinct gene or coupled to a host gene (e.g., intronic source). This distinction is important for regulatory mechanisms as the former will operate as its own transcriptional unit while the latter's transcription will be tied to that of the host protein coding gene. miRNA biogenesis occurs in a stepwise process using multiple RNA-binding proteins (DGCR8) and endoribonucleases (Drosha and Dicer). In the nucleus, the RNA-binding protein DGCR8 binds the RNAspecific endoribonuclease enzyme (ribonuclease type III) Drosha to form the microprocessor complex thereby initiating miRNA processing to cleave the pri-miRNA to the precursor miRNA (pre-miRNA) stem-loop structure. The pre-miRNA is exported to the cytoplasm in which it undergoes further cleavage by Dicer ribonuclease to remove the stem loop. The active strand of the resulting miRNA:miRNA Ã duplex, of approximately 22 nucleotides in length, is incorporated into the RNA-induced silencing complex (RISC), a multisubunit complex composed of Argonaute proteins. The miRNA loaded RISC (miRISC) is now competent to induce gene silencing as the loaded miRNA provides specificity by binding to complementary sequences on the target miRNA 3 0 untranslated region (UTR). Gene silencing proceeds depending on this complementarity between the miRNA and its target mRNA: first, mRNA degradation is favored with complete complementarity (primarily plants) [23] , second, posttranslational repression through mismatch binding of the 3 0 -UTR of the target gene, or third, mRNA destabilization via deadenylation of the poly(A) tail [23] . One of the key features of miRNAs is their redundancy -a single miRNA can regulate multiple target genes and conversely, a single target gene will have multiple miRNAs with the potential to regulate it. This is one of the great challenges in miRNA research, defining which of the many miRNAs that may regulate a specific gene is the most important goal, particularly because many of the miRNA effects are relatively mild.
It is well established now that miRNAs play essential roles in the regulation of multiple vital developmental processes from cell differentiation and organogenesis to the fine-tuning of metabolic and physiochemical responses. As with such a large biological footprint, up to 60% of genes are targeted by miRNAs, abnormalities in miRNA expression could and do pose problems that contribute to the development of disease. Chronic lymphocytic leukemia was among the first human diseases associated with miRNA dysregulation, and dysregulated miRNA expression has since been found in numerous other disease states [26] . This applies to IBD, as there have been a number of recent studies examining the expression of miRNAs in IBD. Distinct miRNA expression patterns have been observed in intestinal biopsies, peripheral blood, and saliva.
MUCOSAL TISSUE MICRORNA EXPRESSION
A number of studies have examined intestinal biopsies as a first step to define the miRNAs that are differentially expressed at the site of IBD pathology. The most common design for these studies was to compare patients with active Crohn's disease or ulcerative colitis versus healthy controls. A few more recent studies have included patients with inactive Crohn's disease or ulcerative colitis as comparison groups. Other studies have examined the miRNA expression in biopsies from areas of active disease versus areas ostensibly normal by endoscopic appearance.
The formative studies into the role of miRNAs in IBD were pioneered by an initial study aimed primarily at delineating miRNAs linked to ulcerative colitis. In this study, Wu et al. [27] compared intestinal biopsies from 15 healthy controls with 15 active ulcerative colitis and 15 inactive ulcerative colitis patients; microscopic colitis, irritable bowel syndrome, and Crohn's disease patients were included in the analysis as well. Among 11 miRNAs identified as having differential expression, miR-21 and miR-29a were found to have elevated expression in the active ulcerative colitis group while miR-192 expression was reduced [27] . Macrophage inflammatory peptide 2-a was identified as a regulatory target of miR-192 and its expression was found to have an inverse relationship with miR-192 [27] . A follow-up study was performed in Crohn's disease colitis and ileitis patients to identify colonic-specific and ileal-specific miRNAs, respectively. miR-23b, miR-191, and miR-106a were elevated while miR-19b and miR-629 were reduced in Crohn's disease colitis [28] . miR-16, miR-21, miR-223, and miR-594 were elevated in Crohn's disease ileitis [28] . In a recent screen for novel regulators of nuclear factor kappa B (NF-kB) using miRNA inhibitors in human colonocytes, seven miRNAs (miR-7, miR-21, miR-146a, miR-181b, miR-214, miR-372, and miR-373) suppressed NF-kB phosphorylation and thus its activity 
CIRCULATING MICRORNA EXPRESSION
The development of an effective noninvasive and accurate test for disease has been a goal in the medical community for many diseases. This has been the case in the clinical diagnosis and treatment of IBD as well. Although endoscopic biopsies and histologic analysis remain the gold standard for diagnosing Crohn's disease and ulcerative colitis, a number of less invasive tests are useful in the clinical management of IBD. Chief among these are fecal calprotectin levels and serum C-reactive protein (CRP) levels. In an effort to improve the quality and accuracy of clinical tests of IBD, circulating miRNA expression has been explored as potential biomarkers of IBD. This is buoyed by several recent studies demonstrating that miRNAs exist in the peripheral blood, serum, and plasma in a stable RNase-resistant form [53, 54] .
Blood microRNA expression
An initial examination of peripheral blood miRNA expression in IBD patients relative to healthy controls revealed elevated expression of miR-199a-5p, miR-340-3p, miR-362-3p, and miR-532-3p in Crohn's disease and ulcerative colitis [50] . miR-28-5p, miR-103-2-5p, and miR-151-5p were additionally elevated in ulcerative colitis while miR-505-5p and miR149-3p were reduced in ulcerative colitis and Crohn's disease, respectively [50] . Duttagupta et al. [55] analyzed miRNA expression after fractionating peripheral blood into microvesicle, peripheral blood mononuclear cell, and platelet fractions. Among 31 candidates within the platelet fraction, miR-188-5p, miR-422a, miR-378, miR-500, miR-501-55, miR-769-5p, and miR-874 were validated to have elevated expression in ulcerative colitis [55] . Zahm et al. [56] identified 11 miRNAs with altered expression in pediatric Crohn's disease (miR-16, let-7b, miR-195, miR-106a, miR-20a, miR-30e, miR-140, miR-484, miR-93, miR-192, and miR-21). Twelve miRNAs (miR-127-3p, miR-491-5p, miR-18a, miR-145, let-7b, miR-185, miR29c, miR-19b, miR-20b, miR-106a, miR-17, and miR-222) were found to be elevated and one (miR-135a) reduced in serum in a study of Crohn's disease and ulcerative colitis patients [57] . Paraskevi et al. [42] reported eleven (miR-16, miR-23a, miR29a, miR-106a, miR-107, miR-126, miR-191, miR199a-5p, miR-200c, miR-362-3p, and miR-532-3p) and five miRNAs (miR-16, miR-21, miR-28-5p, miR-151-5p, and miR-199a-5p) with elevated expression in Crohn's disease and ulcerative colitis peripheral blood, respectively. Another study examining the effects of antitumor necrosis factor-a (TNF-a) induction therapy on miRNA expression in the serum of Crohn's disease patients found elevated expression of let-7d, let-7e, miR-28-5p, miR-221, and miR-224 at week 6 of treatment [58] . Patients who were in remission by week 14 of therapy had elevated levels of let-7d and let-7e compared with nonresponders [58] . ] identified miR-19a-3p and miR-19b-3p as markers of stricturing Crohn's disease; both miRNAs were expressed at lower levels in the serum of Crohn's disease patients with strictures in comparison to nonstricturing Crohn's disease patients.
Salivary microRNA expression
Evaluation of oral fluid (saliva) has become an intriguing diagnostic tool for many diseases due to its The italicized entries denote miRNAs that were reported to have altered expression in two or more independent studies of inflammatory bowel disease patient specimens.
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MICRORNA TARGETING OF INFLAMMATORY BOWEL DISEASE-ASSOCIATED GENES
GWAS, next generation sequencing, and other studies have been instrumental in identifying IBDsusceptibility loci to help understand the complex genetic and biologic pathways underlying disease development [9 & ]. The identification of dysregulated miRNAs in IBD, and their concomitant ability to regulate gene expression, has led to the exploration of the relationship of these miRNAs to these IBD loci. The primary strategies employed have either used IBD-associated miRNAs to search for downstream gene targets or used specific IBD-associated genes to identify regulatory miRNAs. Several laboratories employed the latter candidate gene approach to identify miR-93, miR-106b, miR-130a, and miR-142-3p as regulators of ATG16L1, one of the most common polymorphisms associated with Crohn's disease [59] [60] [61] [62] [63] . Cognizant of the import of NF-kB as a mediator of inflammatory signals in ulcerative colitis, Polytarchou et al. [45 && ] performed a screen in colonocytes to identify miRNAs that altered NF-kB activity; PTEN and PDLIM2 were identified as targets of miR-214 as a result. Through these efforts, a number of IBD-associated genes have been demonstrated to be targets of miRNAs, including genes involved in autophagy (ATG16L1), inflammation (TNF-a), intestinal homeostasis (IL12B), and cytokine production (STAT3) ( Table 3) .
Biologic therapies (primarily humanized monoclonal antibodies) directed against inflammatory mediators involved in the pathophysiology of IBD have revolutionized medical treatment. Tumor necrosis factor antagonists (adalimumab, certolizumab pegol, golimumab, infliximab), anticell adhesion molecule antibodies [natalizumab (anti-ITGA4 antibody) and vedolizumab (anti-LPAM-1 antibody)], and IL12p40 antagonists (ustekinumab) are either currently used for treating IBD [77] [78] [79] [80] [81] [82] . Although these biologics have the advantage of specificity in comparison to glucocorticoids and other immunosuppressive agents (azathioprine, methotrexate), not all patients respond to these medications and some encounter significant side-effects [77] [78] [79] [80] [81] [82] [83] .
Thus, miRNA-based therapeutics could represent a significant alternative to these biologics. The potential of developing miRNAs to target IBD-associated genes is intriguing. However, there are several limitations that have yet to be solved in terms of miRNAbased therapeutics. To be successful, miRNA modulators must be specific, efficient, and safely deliverable to the affected tissue. Off-target side-effects are still a major concern as altering the function of a single miRNA could affect many downstream gene targets and pathways. Site-specific delivery of miRNA therapeutics remains challenging. Nevertheless, preclinical and clinical studies have demonstrated efficacy of miRNA-based therapeutics in cancer, hepatitis C virus infection, and heart disease [84] [85] [86] [87] [88] [89] . MRX34, a liposomal injection of a miR-34a mimic, is being developed as a treatment for liver cancer (Mirna Therapeutics -NCT01829971) and has progressed to the clinical trial stage. A Phase 1 clinical study was recently initiated for MRG-201, a miRNA mimic to micro-RNA-29b, as an antifibrotic agent for cutaneous and pulmonary fibrosis (miRagen Therapeutics).
Several miRNA-based therapeutic studies have reported positive results in animal models of IBD. A study using the azoxymethane (AOM)-dextran sulfate sodium (DSS) mouse model of colitisassociated colorectal cancer development reported tumor suppression in groups treated with a chemical inhibitor (anti-miR) of miR-214 [45 && ]. Anti-miR inhibition of miR-30c and miR-130a reduced intestinal inflammation in a mouse ileal loop model [60] . In interleukin-10 (IL-10) knockout mice and TNBS models of colitis, intestinal inflammation was exacerbated or reduced after intracolonic administration of an anti-miR (for inhibition) or pre-miR miRNA mimic (for overexpression) to miR-141, respectively [90] . Overexpression of miR-146b ameliorated intestinal inflammation in DSStreated mice [91] .
CONCLUSION
Although the exact biological mechanisms are not well understood, it is undeniable that miRNAs play a significant role in the pathogenesis of IBD. This leads to several important conclusions. The first is that several miRNAs were consistently altered across multiple studies reinforcing the import of these miRNAs in IBD. Second, these studies underscore the promise of miRNAs as biomarkers for diagnosing and monitoring disease activity in IBD as well as the potential of miRNA-based therapeutics. Future areas of investigation include continued improvement and refinement of miRNA diagnostics and therapeutics and identification of polymorphisms that impact miRNA binding sites. 48. Takagi T, Naito Y, Mizushima K, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol 2010; 25 (Suppl 1):S129-S133. 49.
